The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20141406: Advent Puma Acquisition Limited; lululemon athletica inc.
20141410: Roadrunner Transportation Systems, Inc.; Platinum Equity Capital Laser Partners I
20141414: Rack Holdings LLC; Odyssey Investment Partners Fund III, LP
20141416: Atlas Copco AB; Keith Jones
20141425: Merck & Co., Inc.; eCardio Diagnostics, LLC
20141426: Kinder Morgan, Inc.; Kinder Morgan Energy Partners, L.P.
20141437: Gannett Co., Inc.; Classified Ventures, LLC
20141336: Liberty Global plc; All3Media Holdings Limited
20141353: Carlyle Partners VI, L.P.; Acosta Holdco, Inc.
20141365: Trian Partners Strategic Investment Fund, L.P.; PepsiCo., Inc.
20141366: Trian Partners Strategic Investment Fund II, L.P.; PepsiCo, Inc.
20141367: Trian Partners, L.P.; PepsiCo, Inc.
20141310: Elliott International Limited; The Interpublic Group of Companies, Inc.
20141311: Elliott Associates, L.P.; The Interpublic Group of Companies, Inc.
20141341: Wells Fargo & Company; MCP I (UELS), LP
20141413: CCMP Capital Investors III, L.P.; Solvay S.A.
Hernandez v. Williams, Zinman & Parham, P.C.
Valeant Pharmaceuticals International and Precision Dermatology, In the Matter of
Valeant Pharmaceuticals International, Inc. and Precision Dermatology, Inc. agreed to sell or relinquish rights to Precision’s branded single-agent topical tretinoins and generic Retin-A, common acne treatments, to settle FTC charges that Valeant’s proposed $475 million acquisition of Precision would likely be anticompetitive. According to the FTC complaint, Valeant’s proposed acquisition of Precision would likely reduce competition in the market for branded and generic single-agent topical tretinoins, and in a separate market for generic Retin-A. The proposed consent order requires Valeant to sell Precision’s assets related to Tretin-X, its branded single-agent topical tretinoin, to Actavis, Inc., and Precision’s assets related to generic Retin-A to Matawan Pharmaceuticals LLC, a subsidiary of Rouses Point Pharmaceuticals.